Polina S. Feoktistova
Research Subjects
Polina S. Feoktistova has a total of 364 co-authors. Here are the top co-authors by number of shared publications:
- Liudmila G. Zhukova
Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia
9 shared publications - Ilya A. Pokataev
Oncology Center No. 1 of the City Clinical Hospital named after S. S. Yudin of the Moscow Department of Health
6 shared publications - Evgeniya S. Kuzmina
Oncology Center No. 1 of the City Clinical Hospital named after S. S. Yudin of the Moscow Department of Health
5 shared publications - Alexey A. Tryakin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - Mikhail Yu. Fedyanin
Blokhin National Medical Research Center of Oncology; Moscow Multidisciplinary Clinical Center “Kommunarka”; Pirogov National Medical and Surgical Center
4 shared publications - Sergey A. Parts
Moscow City Hospital named after S.S. Yudin
4 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 101-106
CA19-9 as a prognostic factor in the treatment of resectable and borderline resectable pancreatic adenocarcinoma
Introduction. The tumor marker CA19-9 is used in the diagnosis and treatment of pancreatic ductal adenocarcinoma (PDAC). Its level correlates with tumor burden and the risk of micrometastases. In recent years, the possibility of using baseline CA19-9 levels to guide treatment strategy has been actively investigated, including the identification of biologically borderline resectable PDAC (CA19-9 ≥ 500 U/mL) and the determination of indications for neoadjuvant chemotherapy even in anatomically resectable tumors. Aim. To evaluate the relationship between baseline CA19-9 levels in patients with resectable and borderline resectable PDAC and overall survival (OS) and event-free survival (EFS), and to identify patient groups that derive the greatest benefit from neoadjuvant chemotherapy. Mat erials and methods. A retrospective analysis of 150 patients treated for resectable and borderline resectable PDAC was performed. In all patients, CA19-9 levels were determined before treatment (in the absence of obstructive jaundice). All patients received chemotherapy with the FOLFIRINOX regimen or its modifications. Results. Patients were divided into three groups according to CA19-9 levels: group 1 (0–100 U/mL), group 2 (>100–500 U/mL), and group 3 (>500 U/mL). Median OS was 47.5 months for group 1 (0–100), 29.0 months for group 2 (>100–500, p = 0.037), and 13.5 months for group 3 (>500, p < 0.001). Median EFS in the > 500 U/mL group was 13.2 months vs 18.5 months in the 0–500 group (p = 0.006). Threshold analysis confirmed a worse prognosis with CA19-9 levels > 100 U/mL (OS 20.3 months vs 47.5 months; p < 0.001) and >500 U/mL (OS 13.5 months vs 35.5 months; p < 0.001). C on cl u si on s . Baseline CA19-9 level is an independent prognostic factor in patients with resectable and borderline resectable PDAC. A level > 500 U/mL is associated with a poor prognosis. Patients with elevated marker levels derive the greatest benefit from neoadjuvant chemotherapy, supporting the inclusion of CA19-9 in decision-making algorithms for treatment personalization.
- 7 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 101-106
Open AccessCA19-9 as a prognostic factor in the treatment of resectable and borderline resectable pancreatic adenocarcinoma
Introduction. The tumor marker CA19-9 is used in the diagnosis and treatment of pancreatic ductal adenocarcinoma (PDAC). Its level correlates with tumor burden and the risk of micrometastases. In recent years, the possibility of using baseline CA19-9 levels to guide treatment strategy has been actively investigated, including the identification of biologically borderline resectable PDAC (CA19-9 ≥ 500 U/mL) and the determination of indications for neoadjuvant chemotherapy even in anatomically resectable tumors. Aim. To evaluate the relationship between baseline CA19-9 levels in patients with resectable and borderline resectable PDAC and overall survival (OS) and event-free survival (EFS), and to identify patient groups that derive the greatest benefit from neoadjuvant chemotherapy. Mat erials and methods. A retrospective analysis of 150 patients treated for resectable and borderline resectable PDAC was performed. In all patients, CA19-9 levels were determined before treatment (in the absence of obstructive jaundice). All patients received chemotherapy with the FOLFIRINOX regimen or its modifications. Results. Patients were divided into three groups according to CA19-9 levels: group 1 (0–100 U/mL), group 2 (>100–500 U/mL), and group 3 (>500 U/mL). Median OS was 47.5 months for group 1 (0–100), 29.0 months for group 2 (>100–500, p = 0.037), and 13.5 months for group 3 (>500, p < 0.001). Median EFS in the > 500 U/mL group was 13.2 months vs 18.5 months in the 0–500 group (p = 0.006). Threshold analysis confirmed a worse prognosis with CA19-9 levels > 100 U/mL (OS 20.3 months vs 47.5 months; p < 0.001) and >500 U/mL (OS 13.5 months vs 35.5 months; p < 0.001). C on cl u si on s . Baseline CA19-9 level is an independent prognostic factor in patients with resectable and borderline resectable PDAC. A level > 500 U/mL is associated with a poor prognosis. Patients with elevated marker levels derive the greatest benefit from neoadjuvant chemotherapy, supporting the inclusion of CA19-9 in decision-making algorithms for treatment personalization.
- Open Access
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 37-45
Comparison of the efficacy of regorafenib and reintroduction of a combination of chemotherapy with anti-EGFR antibody in the third-line treatment of metastatic colorectal cancer with wild-type RAS and BRAF genes of left-sided localization – Results of a multicenter study of real-world practice
Aim. To compare the efficacy and toxicity of regorafenib therapy and the repeated use of anti-EGFR monoclonal antibodies (mAb) combined with chemotherapy (CT) in the third-line treatment of patients with left-sided metastatic colorectal cancer (mCRC) with wild-type RAS and BRAF genes who received anti-EGFR targeted therapy in the first line of treatment. Materials and methods. The database of patients with mCRC from 5 clinics in the Russian Federation was retrospectively analyzed. The study had 3 arms depending on the third-line therapy: regorafenib, reintroduction and rechallenge with the combination of CT and anti-EGFR mAb. In this paper, we present data comparing reintroduction and regorafenib therapy. Results. 132 patients with morphologically confirmed left-sided mCRC with wild-type RAS and BRAF genes who received at least 3 lines of drug therapy from 2014 to 2023 were identified: the first-line therapy included anti-EGFR mAb; 61 patients were reintroduced with a combination of CT with anti-EGFR mAb, and 71 patients received regorafenib in the third-line therapy. Disease control in the reintroduction group was achieved in 43 (70.5%) patients, compared with 18 (25.5%) in the regorafenib group (p = 0.0001). The six-month overall survival (OS) was 76% in the reintroduction group and 55% in the regorafenib group. The median OS in the reintroduction group was 18 months (95% confidence interval [CI] 11.9-24.0 months) and 10 months in the regorafenib group (95% CI 5.3-14.6 months; p = 0.05 according to the log-rank test; p = 0.013 according to the Breslow-Wilcoxon test; p = 0.024 according to the Tarone-Ware test; risk ratio 1.1, 95% CI 0.886-1.408; p = 0.349). Progression-free survival (PFS) was higher in the CT reintroduction group with anti-EGFR mAb (6 months [95% CI 5.3-6.6 months] than in the regorafenib group (3 months [95% CI 2.2-3.7 months]; p = 0.0001 according to the log-rank test, risk ratio 1.23, 95% CI 0.997-1.529; p = 0.053). We found no difference in the incidence of all-grade adverse events between the study groups (p = 0.19), nor in the incidence of grade 3-4 adverse events (p = 0.781). Conclusion. Compared with regorafenib therapy, re-administration of a combination of CT with anti-EGFR targeted therapy in the third-line treatment of patients with left-sided mCRC with wild-type RAS and BRAF genes was associated with a higher rate of disease control and better PFS and 6-month OS.
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 37-45
Open AccessComparison of the efficacy of regorafenib and reintroduction of a combination of chemotherapy with anti-EGFR antibody in the third-line treatment of metastatic colorectal cancer with wild-type RAS and BRAF genes of left-sided localization – Results of a multicenter study of real-world practice
Aim. To compare the efficacy and toxicity of regorafenib therapy and the repeated use of anti-EGFR monoclonal antibodies (mAb) combined with chemotherapy (CT) in the third-line treatment of patients with left-sided metastatic colorectal cancer (mCRC) with wild-type RAS and BRAF genes who received anti-EGFR targeted therapy in the first line of treatment. Materials and methods. The database of patients with mCRC from 5 clinics in the Russian Federation was retrospectively analyzed. The study had 3 arms depending on the third-line therapy: regorafenib, reintroduction and rechallenge with the combination of CT and anti-EGFR mAb. In this paper, we present data comparing reintroduction and regorafenib therapy. Results. 132 patients with morphologically confirmed left-sided mCRC with wild-type RAS and BRAF genes who received at least 3 lines of drug therapy from 2014 to 2023 were identified: the first-line therapy included anti-EGFR mAb; 61 patients were reintroduced with a combination of CT with anti-EGFR mAb, and 71 patients received regorafenib in the third-line therapy. Disease control in the reintroduction group was achieved in 43 (70.5%) patients, compared with 18 (25.5%) in the regorafenib group (p = 0.0001). The six-month overall survival (OS) was 76% in the reintroduction group and 55% in the regorafenib group. The median OS in the reintroduction group was 18 months (95% confidence interval [CI] 11.9-24.0 months) and 10 months in the regorafenib group (95% CI 5.3-14.6 months; p = 0.05 according to the log-rank test; p = 0.013 according to the Breslow-Wilcoxon test; p = 0.024 according to the Tarone-Ware test; risk ratio 1.1, 95% CI 0.886-1.408; p = 0.349). Progression-free survival (PFS) was higher in the CT reintroduction group with anti-EGFR mAb (6 months [95% CI 5.3-6.6 months] than in the regorafenib group (3 months [95% CI 2.2-3.7 months]; p = 0.0001 according to the log-rank test, risk ratio 1.23, 95% CI 0.997-1.529; p = 0.053). We found no difference in the incidence of all-grade adverse events between the study groups (p = 0.19), nor in the incidence of grade 3-4 adverse events (p = 0.781). Conclusion. Compared with regorafenib therapy, re-administration of a combination of CT with anti-EGFR targeted therapy in the third-line treatment of patients with left-sided mCRC with wild-type RAS and BRAF genes was associated with a higher rate of disease control and better PFS and 6-month OS.
- Open Access
- 3 February 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (4) , 11-25
Epidemiology, Predictors, and Impact of Endocrine Immune-Related Adverse Events on Outcomes in Patients with Malignant Tumors
Immune checkpoint inhibitors (ICIs) are widely used in the treatment of malignant tumors, either as monotherapy or in combination with chemotherapy or tyrosine kinase inhibitors (TKIs). Endocrine immune-related adverse events (e-irAEs) are a promising marker of ICI efficacy and patient survival due to their high frequency, early onset, and clear diagnostic criteria. Objective: To conduct an epidemiological analysis of the development of e-irAEs, identify their predictors, and evaluate their impact on cancer outcomes. Materials and methods: This retrospective cohort study included adult patients with solid malignant tumors who received their first administration of ICIs (as monotherapy or in combination with chemotherapy or TKIs) at the SBIH Moscow Clinical Scientific and Practical Center named after A. S. Loginov of DHM from June 1, 2016, to December 31, 2022. Overall survival (OS) was followed up until February 1, 2024. Results were considered statistically significant at p < 0.05. Results: The study included 214 participants with a mean age of 62.6 years (range: 32–91). e-irAEs were reported in 45.3 % of participants, with 6.5 % experiencing two types of e-irAEs. The most common events were primary hypothyroidism (25.7 %), thyrotoxicosis (7.9 %), thyroiditis (7.5 %), secondary adrenal insufficiency (7.5 %), and ICI-induced diabetes mellitus (1.4 %); one patient developed secondary hypothyroidism. 64.2 % of e-irAEs occurred within the first 26 weeks of ICI therapy. The development of e-irAEs correlated with better 1-year OS (11.52 vs. 10.85 months, log-rank p = 0.027), especially among patients with thyroid-related complications (11.6 vs. 10.82 months, log-rank p = 0.009). In the subgroup of participants not receiving TKIs, there was a 44 % higher chance of achieving immune stable disease (iSD, p = 0.04) and a 45 % higher chance of clinical benefit (CBR, p = 0.03). e-irAEs occurred more frequently with concomitant use of incretin-based drugs, calcium channel blockers and antihistamines, and less frequently in patients with a derived neutrophil-to-lymphocyte ratio (dNLR) ≥ 3 at baseline and before the second ICI infusion, and a dNLR > 2.2 before the second ICI infusion. e-irAEs grade ≥ 2 were 2.09 times more often recorded in patients ≥ 60 years old. The combination of ICIs and TKIs increased the risk of primary hypothyroidism 2.3-fold (p = 0.035). Conclusion: The study results indicate a high incidence of e-irAEs. Potential risk factors for their development have been identified. Further validation in prospective studies is required.
- 3 February 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (4) , 11-25
Open AccessEpidemiology, Predictors, and Impact of Endocrine Immune-Related Adverse Events on Outcomes in Patients with Malignant Tumors
Immune checkpoint inhibitors (ICIs) are widely used in the treatment of malignant tumors, either as monotherapy or in combination with chemotherapy or tyrosine kinase inhibitors (TKIs). Endocrine immune-related adverse events (e-irAEs) are a promising marker of ICI efficacy and patient survival due to their high frequency, early onset, and clear diagnostic criteria. Objective: To conduct an epidemiological analysis of the development of e-irAEs, identify their predictors, and evaluate their impact on cancer outcomes. Materials and methods: This retrospective cohort study included adult patients with solid malignant tumors who received their first administration of ICIs (as monotherapy or in combination with chemotherapy or TKIs) at the SBIH Moscow Clinical Scientific and Practical Center named after A. S. Loginov of DHM from June 1, 2016, to December 31, 2022. Overall survival (OS) was followed up until February 1, 2024. Results were considered statistically significant at p < 0.05. Results: The study included 214 participants with a mean age of 62.6 years (range: 32–91). e-irAEs were reported in 45.3 % of participants, with 6.5 % experiencing two types of e-irAEs. The most common events were primary hypothyroidism (25.7 %), thyrotoxicosis (7.9 %), thyroiditis (7.5 %), secondary adrenal insufficiency (7.5 %), and ICI-induced diabetes mellitus (1.4 %); one patient developed secondary hypothyroidism. 64.2 % of e-irAEs occurred within the first 26 weeks of ICI therapy. The development of e-irAEs correlated with better 1-year OS (11.52 vs. 10.85 months, log-rank p = 0.027), especially among patients with thyroid-related complications (11.6 vs. 10.82 months, log-rank p = 0.009). In the subgroup of participants not receiving TKIs, there was a 44 % higher chance of achieving immune stable disease (iSD, p = 0.04) and a 45 % higher chance of clinical benefit (CBR, p = 0.03). e-irAEs occurred more frequently with concomitant use of incretin-based drugs, calcium channel blockers and antihistamines, and less frequently in patients with a derived neutrophil-to-lymphocyte ratio (dNLR) ≥ 3 at baseline and before the second ICI infusion, and a dNLR > 2.2 before the second ICI infusion. e-irAEs grade ≥ 2 were 2.09 times more often recorded in patients ≥ 60 years old. The combination of ICIs and TKIs increased the risk of primary hypothyroidism 2.3-fold (p = 0.035). Conclusion: The study results indicate a high incidence of e-irAEs. Potential risk factors for their development have been identified. Further validation in prospective studies is required.
- Open Access
- 5 December 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (3) , 284-292
Supportive care in oncology as a key to success. A review
The timely selection of appropriate supportive therapy for patients with malignancies is one of the priority tasks of the modern health care system due to the persistent high prevalence, the rapid expansion of antitumor drug therapies, and the increase in the life expectancy of patients. In addition to serious, potentially life-threatening complications, less severe adverse reactions (ADRs) often occur in patients during anticancer therapy, significantly reducing their quality of life. Optimal treatment outcomes, reducing the incidence of complications, and increasing treatment adherence can be achieved by integrating individualized supportive care regimens into a comprehensive management plan for patients with cancer. In real-world practice, oncologists often refer patients with complications to specialized professionals, even in cases where the ADRs do not require third-party consultation, which leads to unreasonable delays in the necessary therapy. To enhance the effectiveness of supportive therapy, it is essential to develop and implement precise clinical algorithms that govern the management of various complications. Our review presents a scheme for the routing of patients with cancer, illustrated by the management of gastrointestinal and hepatobiliary ADRs.
- 5 December 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (3) , 284-292
Open AccessSupportive care in oncology as a key to success. A review
The timely selection of appropriate supportive therapy for patients with malignancies is one of the priority tasks of the modern health care system due to the persistent high prevalence, the rapid expansion of antitumor drug therapies, and the increase in the life expectancy of patients. In addition to serious, potentially life-threatening complications, less severe adverse reactions (ADRs) often occur in patients during anticancer therapy, significantly reducing their quality of life. Optimal treatment outcomes, reducing the incidence of complications, and increasing treatment adherence can be achieved by integrating individualized supportive care regimens into a comprehensive management plan for patients with cancer. In real-world practice, oncologists often refer patients with complications to specialized professionals, even in cases where the ADRs do not require third-party consultation, which leads to unreasonable delays in the necessary therapy. To enhance the effectiveness of supportive therapy, it is essential to develop and implement precise clinical algorithms that govern the management of various complications. Our review presents a scheme for the routing of patients with cancer, illustrated by the management of gastrointestinal and hepatobiliary ADRs.
- Open Access
- 30 November 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (3s1) , 31-37
Предварительные результаты нерандомизированного многоцентрового исследования II фазы комбинации FOLFOX с панитумумабом/цетуксимабом и дабрафенибом в первой линии лечения метастатического колоректального рака с мутацией в гене BRAF и MSS фенотипом
Цель исследования: Изучить эффективность и переносимость терапии по схеме FOLFOX с дабрафенибом и цетуксимабом/панитумумабом в 1 линии терапии метастатического колоректального рака (мКРР) с мутацией в гене BRAF и MSS фенотипом. Методы: Нерандомизрованное многоцентровое несравнительное исследование II фазы по изучению эффективности и безопасности терапии комбинацией режима FOLFOX с дабрафенибом и анти-EGFR в первой линии лечения мКРР с мутацией в гене BRAF и MSS фенотипом. Основные критерии включения: пациенты с гистологически подтвержденным мКРР с мутацией в гене BRAF и MSS фенотипом, удовлетворительной функцией кроветворения и основных показателей внутренних органов, наличием измеряемых проявлений болезни в соответствии с критериями RECIST 1.1. Статистическая гипотеза: нулевая гипотеза — частота объективных ответов 40 %, альтернативная гипотеза — частота объективных ответов 60 %. Для принятия альтернативной гипотезы, при ошибке первого рода 0,05, мощности исследования 90 необходимо включить в исследование 64 пациента. В настоящей статье мы представляем предварительные результаты исследования (NCT06978400). Результаты: На момент сообщения в исследование включено 13 пациентов с мКРР, имеющих мутацию в гене BRAF, ранее не получавших противоопухолевое лечение. Медиана времени наблюдения составила 4,0 месяца (мин. 2 мес. — макс. 19 мес.; 1,4). Соматический статус по шкале ECOG 0 баллов на момент включения в исследование имели 3 пациента (23,1 %), ECOG 1 балл — 9 (69,2 %), ECOG 2 балла 1 пациент (7,7 %). Частичный опухолевый ответ (ЧОО) достигнут у 6 пациентов. Частота объективных ответов в ITT популяции (n = 13) составила 46,1 %. Эффект лечения оценен у 10 (76,9 %). Один пациент умер после 2 курсов лечения от перфорации опухоли, 1 пациент прекратил лечение из‑за токсичности после 1‑ого курса. У 4 пациентов зарегистрирована стабилизация опухолевого процесса (40 %), частичный опухолевый ответ (ЧОО) описан у 6 (60 %) пациентов. Медиана времени до наступления ЧОО с момента начала лечения составила 2 месяца (2,0–4,0).Токсичность описана у 13 (100 %) пациентов в нашем исследовании. Всего на момент анализа данных зарегистрировано 39 нежелательных явлений (НЯ) всех степеней, из них случаев НЯ I–II степени 32 (82 %), III–IV степени — 7 (18,0 %). Отмена лечения потребовалась 1 пациенту в связи с пирексией IV степени. Выводы: Комбинация режима FOLFOX с дабрафенибом и анти-EGFR при первичном анализе демонстрирует управляемый профиль токсичности, высокую частоту контроля над заболеванием.
- 30 November 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (3s1) , 31-37
Open AccessПредварительные результаты нерандомизированного многоцентрового исследования II фазы комбинации FOLFOX с панитумумабом/цетуксимабом и дабрафенибом в первой линии лечения метастатического колоректального рака с мутацией в гене BRAF и MSS фенотипом
Цель исследования: Изучить эффективность и переносимость терапии по схеме FOLFOX с дабрафенибом и цетуксимабом/панитумумабом в 1 линии терапии метастатического колоректального рака (мКРР) с мутацией в гене BRAF и MSS фенотипом. Методы: Нерандомизрованное многоцентровое несравнительное исследование II фазы по изучению эффективности и безопасности терапии комбинацией режима FOLFOX с дабрафенибом и анти-EGFR в первой линии лечения мКРР с мутацией в гене BRAF и MSS фенотипом. Основные критерии включения: пациенты с гистологически подтвержденным мКРР с мутацией в гене BRAF и MSS фенотипом, удовлетворительной функцией кроветворения и основных показателей внутренних органов, наличием измеряемых проявлений болезни в соответствии с критериями RECIST 1.1. Статистическая гипотеза: нулевая гипотеза — частота объективных ответов 40 %, альтернативная гипотеза — частота объективных ответов 60 %. Для принятия альтернативной гипотезы, при ошибке первого рода 0,05, мощности исследования 90 необходимо включить в исследование 64 пациента. В настоящей статье мы представляем предварительные результаты исследования (NCT06978400). Результаты: На момент сообщения в исследование включено 13 пациентов с мКРР, имеющих мутацию в гене BRAF, ранее не получавших противоопухолевое лечение. Медиана времени наблюдения составила 4,0 месяца (мин. 2 мес. — макс. 19 мес.; 1,4). Соматический статус по шкале ECOG 0 баллов на момент включения в исследование имели 3 пациента (23,1 %), ECOG 1 балл — 9 (69,2 %), ECOG 2 балла 1 пациент (7,7 %). Частичный опухолевый ответ (ЧОО) достигнут у 6 пациентов. Частота объективных ответов в ITT популяции (n = 13) составила 46,1 %. Эффект лечения оценен у 10 (76,9 %). Один пациент умер после 2 курсов лечения от перфорации опухоли, 1 пациент прекратил лечение из‑за токсичности после 1‑ого курса. У 4 пациентов зарегистрирована стабилизация опухолевого процесса (40 %), частичный опухолевый ответ (ЧОО) описан у 6 (60 %) пациентов. Медиана времени до наступления ЧОО с момента начала лечения составила 2 месяца (2,0–4,0).Токсичность описана у 13 (100 %) пациентов в нашем исследовании. Всего на момент анализа данных зарегистрировано 39 нежелательных явлений (НЯ) всех степеней, из них случаев НЯ I–II степени 32 (82 %), III–IV степени — 7 (18,0 %). Отмена лечения потребовалась 1 пациенту в связи с пирексией IV степени. Выводы: Комбинация режима FOLFOX с дабрафенибом и анти-EGFR при первичном анализе демонстрирует управляемый профиль токсичности, высокую частоту контроля над заболеванием.
- Open Access
- 30 October 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (3) , 29-39
Results of a prospective single-center randomized study on the role of neoadjuvant chemotherapy in the combined treatment of patients with stage III colon cancer (Node-Rads scores 3-5)
Background: The optimal treatment strategy for patients with stage III colon cancer remains a subject of active research. While adjuvant chemotherapy (ACT) following surgery is the current standard, the potential role of neoadjuvant chemotherapy (NeoACT) in improving treatment outcomes is increasingly being investigated. Objective: To evaluate the impact of neoadjuvant chemotherapy (NeoACT) on surgical outcomes in patients with stage III colon cancer (Node-RADS scores 3-5). Materials and methods: A prospective, single-center, randomized clinical trial included 108 patients divided into two groups: NeoACT (n = 54) and primary surgery (n = 54). Patients in the NeoACT group received chemotherapy using either the CapOX regimen (4 cycles) or FOLFOX6 (6 cycles), followed by surgery. Surgical outcomes (operation duration, intraoperative blood loss, conversion rate, postoperative complications according to Clavien-Dindo, and length ofhospital stay) and pathological findings were analyzed. Results: NeoACT did not adversely affect surgical outcomes. The median operation time was 180 minutes, and the median hospital stay was 8.7 days. Intraoperative blood loss was 50-100 ml in both groups. A statistically significant increase in conversion from laparoscopy to laparotomy was observed in the NeoACT group (p = 0.046). The rates of Clavien-Dindo grade 3a — b complications were 4.2 % and 3.8 %, respectively (p = 1). NeoACT resulted in a higher rate of pNO (p < 0.001), reduced incidence of pT4b (p = 0.053) and pN2 (p = 0.06), and lower presence of lymphovascular invasion (p < 0.001). Only 59.3 % of patients in the NeoACT group required 3 months of ACT, compared to 71.2 % of patients in the primary surgery group who received 6 months (p < 0.001). Conclusion: NeoACT does not increase the rate of postoperative complications and contributes to tumor downstaging, leading to reduced need for adjuvant chemotherapy. The inclusion of patients with Node-RADS scores 4-5 minimized the risk of overtreatment from 25% to 8%.
- 30 October 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (3) , 29-39
Open AccessResults of a prospective single-center randomized study on the role of neoadjuvant chemotherapy in the combined treatment of patients with stage III colon cancer (Node-Rads scores 3-5)
Background: The optimal treatment strategy for patients with stage III colon cancer remains a subject of active research. While adjuvant chemotherapy (ACT) following surgery is the current standard, the potential role of neoadjuvant chemotherapy (NeoACT) in improving treatment outcomes is increasingly being investigated. Objective: To evaluate the impact of neoadjuvant chemotherapy (NeoACT) on surgical outcomes in patients with stage III colon cancer (Node-RADS scores 3-5). Materials and methods: A prospective, single-center, randomized clinical trial included 108 patients divided into two groups: NeoACT (n = 54) and primary surgery (n = 54). Patients in the NeoACT group received chemotherapy using either the CapOX regimen (4 cycles) or FOLFOX6 (6 cycles), followed by surgery. Surgical outcomes (operation duration, intraoperative blood loss, conversion rate, postoperative complications according to Clavien-Dindo, and length ofhospital stay) and pathological findings were analyzed. Results: NeoACT did not adversely affect surgical outcomes. The median operation time was 180 minutes, and the median hospital stay was 8.7 days. Intraoperative blood loss was 50-100 ml in both groups. A statistically significant increase in conversion from laparoscopy to laparotomy was observed in the NeoACT group (p = 0.046). The rates of Clavien-Dindo grade 3a — b complications were 4.2 % and 3.8 %, respectively (p = 1). NeoACT resulted in a higher rate of pNO (p < 0.001), reduced incidence of pT4b (p = 0.053) and pN2 (p = 0.06), and lower presence of lymphovascular invasion (p < 0.001). Only 59.3 % of patients in the NeoACT group required 3 months of ACT, compared to 71.2 % of patients in the primary surgery group who received 6 months (p < 0.001). Conclusion: NeoACT does not increase the rate of postoperative complications and contributes to tumor downstaging, leading to reduced need for adjuvant chemotherapy. The inclusion of patients with Node-RADS scores 4-5 minimized the risk of overtreatment from 25% to 8%.
- Open Access
- 23 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 58-69
Biomarkers of resistance to anti-EGFR therapy in patients with left-sided colorectal cancer: a retrospective NGS analysis
Background: Routine analysis of KRAS, NRAS, BRAF V600 mutations, as well as MSI and HER2 guides treatment selection in colorectal cancer (CRC). Recent findings from the PRESSING and PARADIGM trials have demonstrated that the negative hyperselection of patients based on the results of comprehensive genomic profiling results in better treatment outcomes following anti-EGFR therapy. Study objective: The study aimed to retrospectively analyze the occurrence of alterations associated with potential resistance in samples from CRC patients treated with anti-EGFR therapy.Materials and methods: Patients with confirmed left-sided CRC treated with anti-EGFR therapy due to the lack of RAS / BRAFV600 mutations as per routine PCR were included in the study. FFPE samples were analyzed via NGS (Solo-test Atlas Pro, 38 genes, MSI). Samples determined as RAS / BRAFV600positive by NGS were validated with PCR.Results: A total of 111 samples were analyzed via NGS. A total of 172 alterations in 17 genes were found; alterations in any of the genes covered by the panel were found in 96 (86.5 %) samples. The variant allele frequency ranged 1.3–93.0 %. NGS identified 29 (26.1 %) samples with KRAS (n = 24), NRAS (n = 3) or BRAF p. V600E (n = 4) mutations. Confirmatory PCR testing of 16 RAS / BRAF p. V600E-positive samples resulted in 100 % agreement with NGS. Among RAS / BRAFV600negative samples, 10 (9 %) samples harbored other alterations (ERBB2 amplification, n = 3; PIK3CA, n = 2; MSI, n = 1; BRAF class II mutation, n = 1; ERBB3, n = 1). A total of 11 samples harbored more than 1 alterations associated with potential resistance. BRAF class II / III mutations were found in 4 samples, PIK3CA mutations — in 17 (15.3 %) samples (of those, 5 samples harbored mutations in exon 21).Conclusions: The results of this retrospective analysis demonstrate that a high frequency of false-positive routine PCR results may lead to incorrect indication of anti-EGFR therapy in ~ 26 % cases. Analysis of alterations beyond RAS / BRAFV600 might identify an additional 9 % of patients whose tumors are potentially resistant to anti-EGFR therapy.
- 23 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 58-69
Open AccessBiomarkers of resistance to anti-EGFR therapy in patients with left-sided colorectal cancer: a retrospective NGS analysis
Background: Routine analysis of KRAS, NRAS, BRAF V600 mutations, as well as MSI and HER2 guides treatment selection in colorectal cancer (CRC). Recent findings from the PRESSING and PARADIGM trials have demonstrated that the negative hyperselection of patients based on the results of comprehensive genomic profiling results in better treatment outcomes following anti-EGFR therapy. Study objective: The study aimed to retrospectively analyze the occurrence of alterations associated with potential resistance in samples from CRC patients treated with anti-EGFR therapy.Materials and methods: Patients with confirmed left-sided CRC treated with anti-EGFR therapy due to the lack of RAS / BRAFV600 mutations as per routine PCR were included in the study. FFPE samples were analyzed via NGS (Solo-test Atlas Pro, 38 genes, MSI). Samples determined as RAS / BRAFV600positive by NGS were validated with PCR.Results: A total of 111 samples were analyzed via NGS. A total of 172 alterations in 17 genes were found; alterations in any of the genes covered by the panel were found in 96 (86.5 %) samples. The variant allele frequency ranged 1.3–93.0 %. NGS identified 29 (26.1 %) samples with KRAS (n = 24), NRAS (n = 3) or BRAF p. V600E (n = 4) mutations. Confirmatory PCR testing of 16 RAS / BRAF p. V600E-positive samples resulted in 100 % agreement with NGS. Among RAS / BRAFV600negative samples, 10 (9 %) samples harbored other alterations (ERBB2 amplification, n = 3; PIK3CA, n = 2; MSI, n = 1; BRAF class II mutation, n = 1; ERBB3, n = 1). A total of 11 samples harbored more than 1 alterations associated with potential resistance. BRAF class II / III mutations were found in 4 samples, PIK3CA mutations — in 17 (15.3 %) samples (of those, 5 samples harbored mutations in exon 21).Conclusions: The results of this retrospective analysis demonstrate that a high frequency of false-positive routine PCR results may lead to incorrect indication of anti-EGFR therapy in ~ 26 % cases. Analysis of alterations beyond RAS / BRAFV600 might identify an additional 9 % of patients whose tumors are potentially resistant to anti-EGFR therapy.
- Open Access
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 18-28
What we know about the new coronavirus infection in cancer patients
The article presents data from a retrospective study of COVID-19 outcomes in cancer patients from 24 regions of the Russian Federation.The study included 1,055 patients who had a Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. The mean age was 58.7 years (29–90); 108 (10.2 %) patients were diagnosed with various comorbidities. 627 (59.4 %) were receiving antitumor drug therapy at the time of diagnosis of COVID-19, and 332 (31.5 %) received antitumor chemotherapy.Most patients had asymptomatic or mild COVID-19: asymptomatic in 205 (19.4 %) patients, and mild — in 517 (49.0 %) patients. Moderate / severe COVID-19 was observed in 268 (25.4 %) patients, while severe / critical COVID-19 was diagnosed in 65 (6.2 %). 1204601776 25 (2.4 %) patients died after COVID-19. The average age of cancer patients who died was 66.3 years (31–84). Among the deceased patients, 16 (64.0 %) were women and 9 (36.0 %) were men. To determine the factors increasing the risk of death in cancer patients we performed univariate and multivariate analyses. Conclusions: based on the presented data, the probability of death from COVID-19 was associated with the anti-tumor therapy administered during the disease. This conclusion obliges us to stop antitumor chemotherapy during the COVID-19 disease.
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 18-28
Open AccessWhat we know about the new coronavirus infection in cancer patients
The article presents data from a retrospective study of COVID-19 outcomes in cancer patients from 24 regions of the Russian Federation.The study included 1,055 patients who had a Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. The mean age was 58.7 years (29–90); 108 (10.2 %) patients were diagnosed with various comorbidities. 627 (59.4 %) were receiving antitumor drug therapy at the time of diagnosis of COVID-19, and 332 (31.5 %) received antitumor chemotherapy.Most patients had asymptomatic or mild COVID-19: asymptomatic in 205 (19.4 %) patients, and mild — in 517 (49.0 %) patients. Moderate / severe COVID-19 was observed in 268 (25.4 %) patients, while severe / critical COVID-19 was diagnosed in 65 (6.2 %). 1204601776 25 (2.4 %) patients died after COVID-19. The average age of cancer patients who died was 66.3 years (31–84). Among the deceased patients, 16 (64.0 %) were women and 9 (36.0 %) were men. To determine the factors increasing the risk of death in cancer patients we performed univariate and multivariate analyses. Conclusions: based on the presented data, the probability of death from COVID-19 was associated with the anti-tumor therapy administered during the disease. This conclusion obliges us to stop antitumor chemotherapy during the COVID-19 disease.
- Open Access
- 22 January 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (6)
Toxicity and Safety of Induction Chemotherapy in Locally Advanced Oropharynx, Hypopharynx and Larynx: Non-Randomized Study Comparing DCF and Immunochemotherapy (ICT) with PF-Pembrolizumab
Введение. Стандартный режим индукционной химиотерапии по схеме DCF характеризуется высокой частотой объективного ответа у пациентов с распространенными опухолями головы и шеи. Высокая токсичность режима ограничивает возможность его применения. Проспективное нерандомизированное исследование оценивает эффективность и безопасность иммунохимиотерапии (ИХТ) в качестве индукции. Цель. В этой работе представлены данные сравнения безопасности режима DCF и PF — пембролизумаб, а также риски отказа или незавершения последующей химиолучевой терапии (ХЛТ). Методы. В проспективное нерандомизированное исследование II фазы включались пациенты с III-IV стадией плоскоклеточного местнораспространенного рака ротоглотки, гортани, гортаноглотки в случае положительной экспрессии PD-L1 в опухоли (CPS>=1). Пациентам проводились 3 цикла ИХТ пембролизумабом, цисплатином и 5-фторурацилом с последующим проведением ХЛТ. Группа контроля была оценена ретроспективно. В неё включались пациенты, которые в этот же период времени получали режим DCF (доцетаксел + цисплатин + 5-фторурацил) с последующим проведением ХЛТ. Результаты. В период с апреля 2022 г. по июль 2024 г. включено 120 пациентов для проведения ИХТ. Контрольная группа включила данные по 115 пациентам. Частота нежелательных явлений 3-5 степени составила 30 % и 30,4 % для группы ИХТ и группы DCF (p = 1,00). На этапе индукционной терапии отмечено 6 случаев смерти (5,2 %) в группе DCF, в группе пембролизумаб-PF летальных случаев на этапе индукционной терапии не было (р = 0,01). Высокая доза цисплатина в группе ИХТ ассоциирована с более значимой тенденцией к снижению скорости клубочковой фильтрации (СКФ), в сравнении с группой DCF. Медиана снижения составила СКФ 10,5 %. Во всех случаях снижение СКФ не привело к необходимости проведения гемодиализа. В группе ИХТ 4 пациентам (3,3 %) не проведена лучевая терапия в связи с общим ухудшением здоровья на фоне индукционной терапии, в группе DCF — 12 пациентам (10 %), p = 0,06. Заключение. Индукционный режим PF-пембролизумаб обладает приемлемым профилем токсичности. Дальнейшее изучение эффективности ИХТ представляется актуальной задачей. Исследование зарегистрировано на портале clinicaltrials.gov (номер NCT05551767).
- 22 January 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (6)
Open AccessToxicity and Safety of Induction Chemotherapy in Locally Advanced Oropharynx, Hypopharynx and Larynx: Non-Randomized Study Comparing DCF and Immunochemotherapy (ICT) with PF-Pembrolizumab
Введение. Стандартный режим индукционной химиотерапии по схеме DCF характеризуется высокой частотой объективного ответа у пациентов с распространенными опухолями головы и шеи. Высокая токсичность режима ограничивает возможность его применения. Проспективное нерандомизированное исследование оценивает эффективность и безопасность иммунохимиотерапии (ИХТ) в качестве индукции. Цель. В этой работе представлены данные сравнения безопасности режима DCF и PF — пембролизумаб, а также риски отказа или незавершения последующей химиолучевой терапии (ХЛТ). Методы. В проспективное нерандомизированное исследование II фазы включались пациенты с III-IV стадией плоскоклеточного местнораспространенного рака ротоглотки, гортани, гортаноглотки в случае положительной экспрессии PD-L1 в опухоли (CPS>=1). Пациентам проводились 3 цикла ИХТ пембролизумабом, цисплатином и 5-фторурацилом с последующим проведением ХЛТ. Группа контроля была оценена ретроспективно. В неё включались пациенты, которые в этот же период времени получали режим DCF (доцетаксел + цисплатин + 5-фторурацил) с последующим проведением ХЛТ. Результаты. В период с апреля 2022 г. по июль 2024 г. включено 120 пациентов для проведения ИХТ. Контрольная группа включила данные по 115 пациентам. Частота нежелательных явлений 3-5 степени составила 30 % и 30,4 % для группы ИХТ и группы DCF (p = 1,00). На этапе индукционной терапии отмечено 6 случаев смерти (5,2 %) в группе DCF, в группе пембролизумаб-PF летальных случаев на этапе индукционной терапии не было (р = 0,01). Высокая доза цисплатина в группе ИХТ ассоциирована с более значимой тенденцией к снижению скорости клубочковой фильтрации (СКФ), в сравнении с группой DCF. Медиана снижения составила СКФ 10,5 %. Во всех случаях снижение СКФ не привело к необходимости проведения гемодиализа. В группе ИХТ 4 пациентам (3,3 %) не проведена лучевая терапия в связи с общим ухудшением здоровья на фоне индукционной терапии, в группе DCF — 12 пациентам (10 %), p = 0,06. Заключение. Индукционный режим PF-пембролизумаб обладает приемлемым профилем токсичности. Дальнейшее изучение эффективности ИХТ представляется актуальной задачей. Исследование зарегистрировано на портале clinicaltrials.gov (номер NCT05551767).
- Open Access
- 18 December 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (4) , 447-453
First results of a multicenter, non-randomized, prospective phase II study of the efficacy and safety of induction therapy with pembrolizumab, cisplatin, and 5-fluorouracil in patients with unresectable squamous cell carcinoma of the oropharynx, hypopharynx and larynx
Background. The approved regimen of induction chemotherapy with docetaxel + cisplatin + 5-fluorouracil has high risk of unacceptable toxicity for many patients with advanced head and neck cancer (HNSCC). Toxicity can also compromise the delivery of the following chemoradiation. In order to improve the results of these pts treatment we conducted a prospective multicenter non-randomized phase II study of induction immunochemotherapy followed by (chemo)radiation and here we report first results of objective response rate (ORR), the safety profile of induction therapy and risk of further radiation therapy omission (NCT05551767). Materials and methods. The inclusion criteria were: unresectable stage III–IVA cancer of larynx, oropharynx, hypopharynx, PD-L1-positive (CPS≥1) squamous cell cancer, ECOG 0-2. Included pts received 3 cycles of pembrolizumab 200 mg d1+ cisplatin 100 mg/m2 d1 + 5-fluorouracil 1000 mg/m2/day 1-4 d followed by (chemo-) radiation. Results. Since January 2022 a total of 120 pts were included. Median age was 60 (35–75), the majority were male (105; 87.5%). Objective responses were assessed in 116 of 120 pts. ORR on induction phase was 62.9% (n=73), including 16.4% (n=19) of complete responses. Median change of target lesions was -55% (from -100% to 65%). To date, only 7 pts did not start (chemo)radiation in time due to disease progression (4 pts) or refuse of consent (3 pts). Among 95 pts who completed radiation therapy 94.7% received radiation dose ≥66Gy. The incidence of grade 3-4 adverse events was 30,8%, in 6 (5%) pts it required hospitalization. No grade 5 adverse events were observed. The most common toxicity was hematological with neutropenia grade 3-4 in 28 (23.3%) pts. There was mild immune-related toxicity: 2 (1.7%) pts had skin rash and 1 (0.8%) – hypothyroidism. The use of high dose of cisplatin resulted in a trend to decline glomerular filtration rate (median decrease was 10.5% from baseline) although none of pts required hemodialysis. Conclusion. Induction therapy with pembrolizumab plus cisplatin and 5-fluorouracil provided meaningful ORR and acceptable safety profile in locally advanced HNSCC. It almost did not influence the following radiation therapy omission rate. Further follow-up is needed to assess long-term efficacy.
- 18 December 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (4) , 447-453
Open AccessFirst results of a multicenter, non-randomized, prospective phase II study of the efficacy and safety of induction therapy with pembrolizumab, cisplatin, and 5-fluorouracil in patients with unresectable squamous cell carcinoma of the oropharynx, hypopharynx and larynx
Background. The approved regimen of induction chemotherapy with docetaxel + cisplatin + 5-fluorouracil has high risk of unacceptable toxicity for many patients with advanced head and neck cancer (HNSCC). Toxicity can also compromise the delivery of the following chemoradiation. In order to improve the results of these pts treatment we conducted a prospective multicenter non-randomized phase II study of induction immunochemotherapy followed by (chemo)radiation and here we report first results of objective response rate (ORR), the safety profile of induction therapy and risk of further radiation therapy omission (NCT05551767). Materials and methods. The inclusion criteria were: unresectable stage III–IVA cancer of larynx, oropharynx, hypopharynx, PD-L1-positive (CPS≥1) squamous cell cancer, ECOG 0-2. Included pts received 3 cycles of pembrolizumab 200 mg d1+ cisplatin 100 mg/m2 d1 + 5-fluorouracil 1000 mg/m2/day 1-4 d followed by (chemo-) radiation. Results. Since January 2022 a total of 120 pts were included. Median age was 60 (35–75), the majority were male (105; 87.5%). Objective responses were assessed in 116 of 120 pts. ORR on induction phase was 62.9% (n=73), including 16.4% (n=19) of complete responses. Median change of target lesions was -55% (from -100% to 65%). To date, only 7 pts did not start (chemo)radiation in time due to disease progression (4 pts) or refuse of consent (3 pts). Among 95 pts who completed radiation therapy 94.7% received radiation dose ≥66Gy. The incidence of grade 3-4 adverse events was 30,8%, in 6 (5%) pts it required hospitalization. No grade 5 adverse events were observed. The most common toxicity was hematological with neutropenia grade 3-4 in 28 (23.3%) pts. There was mild immune-related toxicity: 2 (1.7%) pts had skin rash and 1 (0.8%) – hypothyroidism. The use of high dose of cisplatin resulted in a trend to decline glomerular filtration rate (median decrease was 10.5% from baseline) although none of pts required hemodialysis. Conclusion. Induction therapy with pembrolizumab plus cisplatin and 5-fluorouracil provided meaningful ORR and acceptable safety profile in locally advanced HNSCC. It almost did not influence the following radiation therapy omission rate. Further follow-up is needed to assess long-term efficacy.